Compare Stocks: EQ, EIKN, PRTA, and KYTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EIKN Eikon Therapeutics	$8.29 +2.0%	$10.04	$7.72 ▼ $17.40	$486.40M	N/A	592,095 shs	710,004 shs
EQ Equillium	$1.72 -1.7%	$2.25	$0.76 ▼ $3.54	$122.38M	1.81	551,543 shs	280,696 shs
KYTX Kyverna Therapeutics	$6.99 -1.1%	$7.81	$5.30 ▼ $13.67	$464.44M	1.98	687,159 shs	3.28 million shs
PRTA Prothena	$8.32 -4.1%	$8.92	$7.73 ▼ $11.80	$454.42M	-0.33	407,954 shs	426,062 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EIKN Eikon Therapeutics	+1.97%	-3.60%	-33.94%	-27.60%	+828,999,900.00%
EQ Equillium	-1.71%	-8.99%	-21.10%	-43.07%	+19.44%
KYTX Kyverna Therapeutics	-1.13%	-0.71%	-20.93%	-17.18%	+8.54%
PRTA Prothena	-4.15%	-1.65%	-11.68%	-16.97%	-10.73%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EIKN Eikon Therapeutics	$8.29 +2.0%	$10.04	$7.72 ▼ $17.40	$486.40M	N/A	592,095 shs	710,004 shs
EQ Equillium	$1.72 -1.7%	$2.25	$0.76 ▼ $3.54	$122.38M	1.81	551,543 shs	280,696 shs
KYTX Kyverna Therapeutics	$6.99 -1.1%	$7.81	$5.30 ▼ $13.67	$464.44M	1.98	687,159 shs	3.28 million shs
PRTA Prothena	$8.32 -4.1%	$8.92	$7.73 ▼ $11.80	$454.42M	-0.33	407,954 shs	426,062 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EIKN Eikon Therapeutics	+1.97%	-3.60%	-33.94%	-27.60%	+828,999,900.00%
EQ Equillium	-1.71%	-8.99%	-21.10%	-43.07%	+19.44%
KYTX Kyverna Therapeutics	-1.13%	-0.71%	-20.93%	-17.18%	+8.54%
PRTA Prothena	-4.15%	-1.65%	-11.68%	-16.97%	-10.73%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EIKN Eikon Therapeutics	2.50	Moderate Buy	$25.00	201.57% Upside
EQ Equillium	2.91	Moderate Buy	$7.57	340.20% Upside
KYTX Kyverna Therapeutics	2.60	Moderate Buy	$30.00	329.18% Upside
PRTA Prothena	2.75	Moderate Buy	$24.57	195.33% Upside

Current Analyst Ratings Breakdown

Latest EQ, EIKN, PRTA, and KYTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/21/2026	EQ Equillium	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/21/2026	KYTX Kyverna Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/16/2026	EIKN Eikon Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/9/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/7/2026	EIKN Eikon Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/4/2026	EQ Equillium	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
8/21/2026	EIKN Eikon Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/14/2026	EIKN Eikon Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Underperform	$5.00 ➝ $4.00
8/11/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	EQ Equillium	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/3/2026	EIKN Eikon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E-) ➝ Sell (E)

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
EQ Equillium	$41.10M	2.65	N/A	N/A	$0.47 per share	3.66
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	$3.85 per share	N/A
PRTA Prothena	$54.53M	7.99	N/A	N/A	$5.21 per share	1.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EIKN Eikon Therapeutics	-$324.25M	-$4.09	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EQ Equillium	-$22.40M	-$0.20	N/A	N/A	N/A	N/A	-41.15%	-38.29%	11/12/2026 (Estimated)
KYTX Kyverna Therapeutics	-$161.31M	-$2.94	N/A	N/A	N/A	N/A	-81.92%	-63.74%	11/11/2026 (Estimated)
PRTA Prothena	-$244.09M	-$0.84	N/A	N/A	3.17	-80.68%	-16.45%	-14.51%	11/5/2026 (Estimated)

Latest EQ, EIKN, PRTA, and KYTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	EIKN Eikon Therapeutics	-$1.61	-$1.63	-$0.02	-$1.63	N/A	N/A
8/13/2026	Q2 2026	EQ Equillium	-$0.0540	-$0.04	+$0.0140	-$0.04	N/A	N/A
8/11/2026	Q2 2026	KYTX Kyverna Therapeutics	-$0.6783	-$0.63	+$0.0483	-$0.63	N/A	N/A
8/6/2026	Q2 2026	PRTA Prothena	-$0.39	-$0.32	+$0.07	-$0.36	$0.42 million	$1.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A
EQ Equillium	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EIKN Eikon Therapeutics	N/A	9.89	9.89
EQ Equillium	N/A	23.40	23.40
KYTX Kyverna Therapeutics	0.15	9.06	9.06
PRTA Prothena	N/A	25.05	25.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EIKN Eikon Therapeutics	N/A
EQ Equillium	27.05%
KYTX Kyverna Therapeutics	18.08%
PRTA Prothena	97.08%

Insider Ownership

Company	Insider Ownership
EIKN Eikon Therapeutics	N/A
EQ Equillium	17.84%
KYTX Kyverna Therapeutics	17.60%
PRTA Prothena	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EIKN Eikon Therapeutics	384	54.17 million	N/A	N/A
EQ Equillium	14	63.41 million	52.10 million	Not Optionable
KYTX Kyverna Therapeutics	149	61.84 million	50.96 million	Optionable
PRTA Prothena	67	52.35 million	46.91 million	Optionable

EQ, EIKN, PRTA, and KYTX Headlines

Recent News About These Companies

William Scully Acquires 100,000 Shares of Prothena (NASDAQ:PRTA) Stock

September 23 at 4:23 AM | americanbankingnews.com

Prothena stock falls to USD 8.51 as earnings beat estimates

September 22 at 6:39 PM | ad-hoc-news.deA

Prothena (NASDAQ:PRTA) Major Shareholder William Scully Purchases 100,000 Shares

September 22 at 4:22 AM | insidertrades.com

Prothena Corp Public Ltd Insider Bought Shares Worth $843,460, According to a Recent SEC Filing

September 21, 2026 | marketscreener.comM

William Scully Buys 100,000 Shares of Prothena (NASDAQ:PRTA) Stock

September 21, 2026 | marketbeat.com

4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day

September 21, 2026 | zacks.com

[PRTA] Attention!! Reaching the 'Previous Buy Price' of Big Players Who Sold at the Top! Prothena Dip-Buying Strategy Targeting Chart Pivot Points

September 18, 2026 | note.comN

Prothena Corporation plc (NASDAQ:PRTA) Receives Average Recommendation of "Moderate Buy" from Analysts

September 18, 2026 | marketbeat.com

Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 9, 2026 | businesswire.com

Prothena (NASDAQ:PRTA) Major Shareholder Purchases 27,000 Shares of Stock

September 4, 2026 | insidertrades.com

Prothena (NASDAQ:PRTA) Major Shareholder Purchases $255,690.00 in Stock

September 3, 2026 | marketbeat.com

Prothena (NASDAQ:PRTA) Share Price Passes Below Two Hundred Day Moving Average - What's Next?

September 1, 2026 | marketbeat.com

Prothena (NASDAQ:PRTA) Major Shareholder William Scully Purchases 50,000 Shares

August 22, 2026 | insidertrades.com

KMDA or PRTA: Which Is the Better Value Stock Right Now?

August 14, 2026 | zacks.com

RBC Capital Keeps Their Hold Rating on Prothena (PRTA)

August 8, 2026 | theglobeandmail.com

PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

August 7, 2026 | zacks.com

Prothena: Q2 Earnings Snapshot

August 6, 2026 | chron.com

Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates

August 6, 2026 | zacks.com

Prothena Reports Second Quarter 2026 Financial Results and Business Highlights

August 6, 2026 | businesswire.com

Prothena (NASDAQ:PRTA) Insider Sells $64,897.14 in Stock

July 31, 2026 | insidertrades.com

Prothena to Report Second Quarter 2026 Financial Results on August 6

July 30, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EQ, EIKN, PRTA, and KYTX Company Descriptions

Eikon Therapeutics NASDAQ:EIKN

$8.29 +0.16 (+1.97%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$8.35 +0.06 (+0.70%)

As of 09/24/2026 07:54 PM Eastern

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers. Our Chair and Chief Executive Officer, Dr. Roger M. Perlmutter, M.D., Ph.D., and our Chief Medical Officer, Dr. Roy Baynes, M.D., Ph.D., together have a proven track record of identifying, developing, and commercializing some of the most impactful drugs ever brought to market, including pembrolizumab, currently the world’s best-selling oncology therapeutic and arguably the most important anti-neoplastic agent ever introduced into clinical practice. While Drs. Perlmutter and Baynes’ track records do not provide a guarantee of future clinical success, and any products developed by us may not achieve the regulatory or commercial success of products that Drs. Perlmutter and Baynes were previously involved in developing, their experience provides valuable insight and strategic guidance to our drug development efforts. Our broader leadership team consists of former senior leaders at global pharmaceutical companies, who have successfully collaborated across several decades on the discovery, development, and commercialization of over 100 new molecular entities. Our strategy centers around deploying our technology platform, including our proprietary single molecule tracking, or SMT, system, to develop internally-derived novel therapies, while also leveraging the deep expertise of our management team to opportunistically in-license promising assets. Our most advanced product candidate, EIK1001, a toll-like receptor, or TLR, 7/8 dual-agonist, is currently in a global Phase 2/3 registrational trial in combination with pembrolizumab for the treatment of patients with advanced melanoma. This Phase 2/3 trial is designed to proceed to completion, subject to interim analysis by a data monitoring committee, and to form the basis for registration. We are also evaluating EIK1001 in combination with both pembrolizumab and histology appropriate chemotherapy for the treatment of patients with non-small cell lung cancer, or NSCLC, in a Phase 2 trial, as well as a Phase 2/3 registrational trial for which we recently initiated site selection. We are also conducting Phase 1/2 trials of each of our selective PARP1 inhibitor product candidates, EIK1003 and EIK1004, in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant candidate EIK1004, to address brain metastases and primary brain malignancies. In addition, we have recently initiated a Phase 1/2 trial in patients with advanced solid tumors for EIK1005, our Werner, or WRN, helicase inhibitor that emerged through internal research using our technology platform, which will ultimately be evaluated for the treatment of patients with microsatellite instability-high, or MSI-high, tumors. We were incorporated in Delaware in July 2019. Our principal executive offices are located in Millbrae, California.

Equillium NASDAQ:EQ

$1.72 -0.03 (-1.71%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$1.78 +0.06 (+3.43%)

As of 09/24/2026 07:30 PM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Kyverna Therapeutics NASDAQ:KYTX

$6.99 -0.08 (-1.13%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$7.06 +0.07 (+1.06%)

As of 09/24/2026 07:55 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Prothena NASDAQ:PRTA

$8.32 -0.36 (-4.15%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$8.34 +0.02 (+0.18%)

As of 09/24/2026 07:30 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EQ, EIKN, PRTA, and KYTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EQ, EIKN, PRTA, and KYTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EQ, EIKN, PRTA, and KYTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EQ, EIKN, PRTA, and KYTX Company Descriptions

Eikon Therapeutics NASDAQ:EIKN

Equillium NASDAQ:EQ

Kyverna Therapeutics NASDAQ:KYTX

Prothena NASDAQ:PRTA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EQ, EIKN, PRTA, and KYTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EQ, EIKN, PRTA, and KYTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EQ, EIKN, PRTA, and KYTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EQ, EIKN, PRTA, and KYTX Company Descriptions

Eikon Therapeutics NASDAQ:EIKN

Equillium NASDAQ:EQ

Kyverna Therapeutics NASDAQ:KYTX

Prothena NASDAQ:PRTA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools